Filing Details

Accession Number:
0001179110-14-004577
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-05 18:33:53
Reporting Period:
2014-03-03
Filing Date:
2014-03-05
Accepted Time:
2014-03-05 18:33:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1436304 Kythera Biopharmaceuticals Inc KYTH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1416180 R Keith Leonard 27200 West Agoura Rd
Suite 200
Calabasas CA 91301
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-03-03 6,282 $48.86 939,698 No 4 S Indirect See footnote
Common Stock Disposition 2014-03-03 6,718 $49.53 932,980 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 52,795 Indirect See footnote
Common Stock 52,795 Indirect See footnote
Common Stock 189 Indirect See footnote
Common Stock 189 Indirect See footnote
Footnotes
  1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2014.
  2. Shares held by Leonard Family Trust, dated August 28, 1996, Keith Richard Leonard, Jr. and Nanette LaRosa Leonard, Trustees.
  3. Shares held by Keith Richard Leonard, Jr., Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee.
  4. Shares held by Nanette LaRosa Leonard, Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee.
  5. Shares held by Keith R. Leonard III. Keith R. Leonard III is the son of the Reporting Person.
  6. Shares held by Nina R. Leonard. Nina R. Leonard is the daughter of the Reporting Person.
  7. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $48.36 to $49.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $49.02 to $50.02, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.